Compare BIRD & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIRD | YI |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Apparel | Retail-Drug Stores and Proprietary Stores |
| Sector | Consumer Discretionary | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1M | 30.9M |
| IPO Year | 2021 | 2018 |
| Metric | BIRD | YI |
|---|---|---|
| Price | $2.34 | $3.37 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 649.8K | 6.0K |
| Earning Date | 05-07-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $152,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $35.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.15 | $2.48 |
| 52 Week High | $24.31 | $11.17 |
| Indicator | BIRD | YI |
|---|---|---|
| Relative Strength Index (RSI) | 40.84 | 39.01 |
| Support Level | $2.22 | $2.48 |
| Resistance Level | $2.71 | $3.98 |
| Average True Range (ATR) | 0.20 | 0.21 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 13.33 | 39.36 |
Smartbird Inc delivers dedicated AI infrastructure as a service, giving organizations the performance, control, and security of a private AI cluster without requiring them to finance, operate, or maintain the underlying infrastructure. Smartbird manages the entire lifecycle, from procurement and deployment to operations and hardware refreshes, so customers can focus on AI workloads, not AI infrastructure.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.